A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BRENSOCATIB IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS – THE ASPEN TRIAL

This abstract has been temporarily removed at the request of the author. A replacement will appear as soon as possible, or the abstract will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.